Description Results NMA

isradipine up to 5mg 3 times daily (n=19)

vs.

placebo (n=0)

Double blind

Parallel groups

Sample size: 19/0

Primary endpoint: Hemodynamic

FU duration: 3 months

all cause death 0.89 [0.35; 2.28]

coronary heart disease 1.20 [0.37; 3.89]

heart failure ∞ [NaN; ∞]

non fatal MI 1.20 [0.37; 3.89]

stroke (fatal & non fatal) 2.00 [0.50; 7.93]

Major cardiovascular events 1.54 [0.73; 3.25]

isradipine 2.5-5.0 mg twice daily (n=442)

vs.

hydrochlorothiazide 12.5-25 mg Twice daily (n=441)

Sample size: 442/441

Primary endpoint: intimal-medial thickness

FU duration: 3y